Advertisement
Advertisement

BBLG

BBLG logo

Bone Biologics Corp Common Stock

1.70
USD
Sponsored
+0.01
+0.30%
Jan 29, 15:50 UTC -5
Closed
exchange

After-Market

1.70

0.00
0.00%

BBLG Earnings Reports

Positive Surprise Ratio

BBLG beat 12 of 15 last estimates.

80%

Next Report

Date of Next Report
Feb 24, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.34
Implied change from Q3 25 (Revenue/ EPS)
--
/
-8.11%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-90.76%

Bone Biologics Corp Common Stock earnings per share and revenue

On Nov 14, 2025, BBLG reported earnings of -0.37 USD per share (EPS) for Q3 25, beating the estimate of -1.25 USD, resulting in a 70.51% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.69% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.34 USD, with revenue projected to reach -- USD, implying an decrease of -8.11% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Bone Biologics Corp Common Stock reported EPS of -$0.37, beating estimates by 70.51%, and revenue of $0.00, 0% as expectations.
The stock price moved up 1.69%, changed from $1.60 before the earnings release to $1.63 the day after.
The next earning report is scheduled for Feb 24, 2026.
Based on 3 analysts, Bone Biologics Corp Common Stock is expected to report EPS of -$0.34 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement